Publications

Chakravaty et al. provide a comprehensive review of the scientific basis for kinase inhibitor use, and summarise experience from clinical trials in tofacitinib and fostamatinib, plus promising clinical data for p38-MAPK inhibitors and P13K? and P13Kd. The authors highlight potential future directions and challenges in kinase inhibitor research, including the emergence of kinases upstream of p38, such as MKK-3 and MKK-6, and the potential of BTK inhibition. One of the challenges of kinase inhibition is that several of the kinases involved in RA pathogenesis are also involved in homeostasis; thus the future of kinase inhibition could lie in key to successful development of therapeutic strategies that selectively block pathogenic cascades yet preserve homeostatic pathways.